Literature DB >> 25337217

L-22 enhances the invasiveness of endometrial stromal cells of adenomyosis in an autocrine manner.

Qing Wang1, Li Wang2, Jun Shao1, Yan Wang1, Li-Ping Jin3, Da-Jin Li1, Ming-Qing Li3.   

Abstract

It has reported that interleukin-22 (IL-22) promotes the invasion of tumor cells. IL-22 in the endometriotic milieu stimulates the proliferation of human endometrial stromal cells (ESCs). The present study aimed to elucidate whether and how IL-22 regulates the invasion of ESCs from adenomyosis. The expression of IL-22 and its receptors in normal endometrium, eutopic endometrium and ectopic lesion was analyzed by immunohistochemistry; the invasiveness of ESCs in vitro was verified by Matrigel invasion assay; and the effects of IL-22 on the correspondent functional molecules were investigated by ELISA and flow cytometry. Here we found that IL-22 and its receptors IL-22R1 and IL-10R2 in eutopic endometrium and ectopic lesion of adenomyosis were significantly higher than that of normal endometrium. Recombinant human IL-22 (rhIL-22) increased IL-22R1 and IL-10R2 levels on ESCs. Moreover, rhIL-22 promoted the invasiveness of ESCs, and inhibited the expression of metastasis suppressor gene CD82, stimulated the secretion of IL-8, RANTES, IL-6 and VEGF of ESCs. On the contrary, the neutralizing antibody for IL-22 reversed these effects. Our current study has demonstrated that IL-22 has a positive feedback on the expression of its receptors IL-22R1 and IL-10R2 on ESCs. This autocrine effect of IL-22 promotes the invasion of ESCs possibly through regulating invasion-related molecules, suggesting that the abnormal high expression of IL-22 may play an important role in ESCs invasion and finally contribute to the origin and development of adenomyosis.

Entities:  

Keywords:  IL-22; adenomyosis; endometrial stromal cells; invasion

Mesh:

Substances:

Year:  2014        PMID: 25337217      PMCID: PMC4203188     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  42 in total

Review 1.  Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy.

Authors:  A S Uduwela; M A Perera; L Aiqing; I S Fraser
Journal:  Obstet Gynecol Surv       Date:  2000-06       Impact factor: 2.347

2.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

3.  Adenomyosis--a result of disordered stromal differentiation.

Authors:  E Parrott; M Butterworth; A Green; I N White; P Greaves
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Increased interleukin-6 messenger RNA expression in macrophage-cocultured endometrial stromal cells in adenomyosis.

Authors:  Jehn-Hsiahn Yang; Ming-Yih Wu; Daw-Yuan Chang; Chien-Huei Chang; Yu-Shih Yang; Hong-Nerng Ho
Journal:  Am J Reprod Immunol       Date:  2006-03       Impact factor: 3.886

5.  Expression of interleukin-8 and monocyte chemotactic protein-1 in adenomyosis.

Authors:  E Cagnur Ulukus; Murat Ulukus; Yasemin Seval; Wenxin Zheng; Aydin Arici
Journal:  Hum Reprod       Date:  2005-06-24       Impact factor: 6.918

6.  IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis.

Authors:  Kerstin Wolk; Ellen Witte; Elizabeth Wallace; Wolf-Dietrich Döcke; Stefanie Kunz; Khusru Asadullah; Hans-Dieter Volk; Wolfram Sterry; Robert Sabat
Journal:  Eur J Immunol       Date:  2006-05       Impact factor: 5.532

Review 7.  Pathophysiology of adenomyosis.

Authors:  A Ferenczy
Journal:  Hum Reprod Update       Date:  1998 Jul-Aug       Impact factor: 15.610

8.  Evidence for estrogen synthesis in adenomyotic tissues.

Authors:  T Yamamoto; T Noguchi; T Tamura; J Kitawaki; H Okada
Journal:  Am J Obstet Gynecol       Date:  1993-09       Impact factor: 8.661

9.  IL-22 increases the innate immunity of tissues.

Authors:  Kerstin Wolk; Stefanie Kunz; Ellen Witte; Markus Friedrich; Khusru Asadullah; Robert Sabat
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

10.  IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling.

Authors:  H Fukui; X Zhang; C Sun; K Hara; S Kikuchi; T Yamasaki; T Kondo; T Tomita; T Oshima; J Watari; J Imura; T Fujimori; M Sasako; H Miwa
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

View more
  5 in total

1.  Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells.

Authors:  Wen-Qing Shang; Jia-Jun Yu; Lei Zhu; Wen-Jie Zhou; Kai-Kai Chang; Qing Wang; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

2.  Expression of CXCL12 and its receptor CXCR4 in patients with adenomyosis.

Authors:  Juan Li; Geping Yin; Ming Chen; Shujun Yang; Aifang Wu; Jing Liang; Zheng Yuan
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

Review 3.  Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Sci       Date:  2022-07-15       Impact factor: 2.924

4.  Transcriptome analysis of eutopic endometrial stromal cells in women with adenomyosis by RNA-sequencing.

Authors:  Lin Gan; Yongrong Li; Yan Chen; Meihua Huang; Jian Cao; Meiling Cao; Zhihui Wang; Guiping Wan; Tao Gui
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

5.  Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.

Authors:  Marissa J Harmsen; Caroline F C Wong; Velja Mijatovic; Arjan W Griffioen; Freek Groenman; Wouter J K Hehenkamp; Judith A F Huirne
Journal:  Hum Reprod Update       Date:  2019-09-11       Impact factor: 15.610

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.